Can a new drug combo make pancreatic cancer surgery more effective?
NCT ID NCT07806110
First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time
Summary
This phase II trial tests whether adding an experimental drug called SHR-1701 to a standard chemotherapy regimen can improve outcomes for people with pancreatic cancer that is resectable or borderline resectable. Participants receive the combination before surgery, with the goal of shrinking tumors to allow for complete removal. The main measure of success is the rate of R0 resection, meaning surgery with clear margins, which is linked to better long-term survival.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- SHR-1701 combined with liposomal irinotecan, nab-paclitaxel, and gemcitabine
- What this could lead to
- If successful, this approach could shrink pancreatic tumors before surgery, making complete removal more likely and potentially extending survival for patients with resectable or borderline resectable disease.
- What could go wrong
- This is a phase II trial with a modest number of participants, so results may not hold up in larger studies. The drug combination carries risks of side effects, and not all patients will benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 62 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age ≥18 years, male or female; 2. Resectable or borderline resectable pancreatic cancer 3. No prior anti-tumor therapy (including radiotherapy, ablation, chemotherapy, targeted therapy, immunotherapy, etc.) or investigational drug treatment 4. At least one measurable lesion as a target lesion according to RECIST v1.1 criteria 5. ECOG performance status: 0-1 6. Expected survival time ≥3 months 7. Adequate major organ function Exclusion Criteria: 1. Patients with pancreatic tumors originating from non-pancreatic ductal epithelium, including pancreatic neuroendocrine carcinoma, pancreatic acinar cell carcinoma, pancreatoblastoma, and solid-pseudopapillary neoplasm 2. Known central nervous system (CNS) metastases 3. Severe gastrointestinal dysfunction (e.g., GI bleeding, obstruction, Grade \>2 inflammation, or Grade \> 1 diarrhea); 4. Symptomatic ascites requiring paracentesis or drainage, or patients who have received ascites drainage within the past 3 months (except for those with asymptomatic, controllable minimal ascites detected solely on imaging); 5. Current interstitial lung disease (ILD) or pneumonitis; 6. Known peripheral neuropathy (CTCAE Grade ≥3); 7. Coagulation dysfunction, bleeding tendency, or current thrombolytic or full-dose anticoagulant therapy. 8. Uncontrolled clinical cardiovascular symptoms or diseases; 9. Malignancy other than pancreatic cancer within 5 years prior to randomization, with the exception of adequately treated cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin; 10. Known hypersensitivity to liposomal irinotecan, other liposomal formulations, gemcitabine, nab-paclitaxel, retlirafusp alfa injection, or any component of these products; 11. Known Acquired Immunodeficiency Syndrome (AIDS), positive HIV antibody test, or active syphilis infection; 12. History of neurological or psychiatric disorders, including epilepsy or dementia
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pancreas ductal adenocarcinoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Hospital of Jilin University
Changchun, Jilin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.